Rationale: Lanadelumab, a fully human monoclonal antibody and inhibitor of plasma kallikrein, is indicated for long-term prophylaxis (LTP) of type I and II HAE with C1-INH deficiency in patients ≥ 12 years. The gene discussed is SERPING1; the disease is hyperinsulinemic hypoglycemia, familial, 4.